

Title

Economic Burden of Chronic Hand Eczema: A Review

Journal

American Journal of Clinical Dermatology

Authors

Prof April Armstrong¹

Julie Hahn-Pedersen²

Chris Bartlett³

Julie Glanville³

Prof Jacob P. Thyssen⁴

1 Department of Dermatology, Keck School of Medicine at University of Southern California, California, United States

2 LEO Pharma A/S, Ballerup, Denmark

3 York Health Economics Consortium Ltd, York, United Kingdom

4 Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Denmark

Corresponding Author Details

Chris Bartlett

Chris.bartlett@york.ac.uk

York Health Economics Consortium Ltd, York, YO10 5NQ, United Kingdom

01904 323620

SUPPLEMENTARY ONLINE RESOURCE CONTENTS

Online Resource 1 **Search Strategy**

Online Resource 2 **Quality Assessment Tables**

Table S1 Risk of bias assessment of cost studies

Table S2 Risk of bias assessment of economic models (NICE cost-effectiveness checklist, adapted from Drummond, 1996 [1])

Table S3 Risk of bias assessment of RCTs (Cochrane [2, 3])

Table S4 Risk of bias assessment of cohort studies (CRD cohort checklist [4])

Table S5 Risk of bias assessment of cross-sectional studies - Adapted Newcastle Ottawa Scale (Herzog 2013[5])

Online Resource 1 – Search Strategy

The review was informed by a number of separate searches. The original 2018 searches and the 2020 update searches included six separate sets of MEDLINE and Embase database searches, plus searches of additional databases and websites. Full search strategies for all resources searched for the 2020 search are shown below.

The search made use, where available, of subject headings, as well as words in the title, abstract and authors keywords to find records reporting on hand eczema or hand dermatitis. The subject searches were then combined with filters to find particular types of publication such as reviews.

In the MEDLINE strategies, animal studies were removed using a standard algorithm and publication types that were unlikely to yield relevant information, such as comments, editorial, news, letters and case reports were excluded.

Search results were downloaded and loaded into EndNote. The results were deduplicated using several algorithms and the duplicate references held in a separate EndNote database. Results from resources that do not allow export in a format compatible with EndNote were saved in Word or Excel documents and manually deduplicated.

The full searches are reported below.

SEARCH STRATEGIES

A.1: Source: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily

Interface / URL: Ovid SP

Database coverage dates: 1946 to 02/10/2020

Search date: 08/10/2020

Retrieved records: 653

Search strategy:

Note: This strategy identified RCTs and patient preference studies.

- 1 Skin Diseases, Eczematous/ (69)
- 2 Eczema/ (10998)
- 3 Eczema, Dyshidrotic/ (282)
- 4 exp Dermatitis, Contact/ (34116)
- 5 (eczema\$ or dermatos\$ or dermatit\$).ti,ab,kf. (92408)
- 6 (dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite).ti,ab,kf. (2117)
- 7 or/1-6 (111678)
- 8 exp Hand/ (79492)
- 9 (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits or finger or fingers or nail or nails).ti,ab,kf. (579808)
- 10 or/8-9 (605744)
- 11 7 and 10 (6793)
- 12 Hand Dermatoses/ (7717)

13 or/11-12 (12570)
 14 Patient Preference/ (8733)
 15 prefer\$.ti,ab,kf. (474065)
 16 or/14-15 (476887)
 17 13 and 16 (123)
 18 randomized controlled trial.pt. (514150)
 19 controlled clinical trial.pt. (93863)
 20 randomized.ab. (506720)
 21 placebo.ab. (215342)
 22 clinical trials as topic.sh. (193096)
 23 randomly.ab. (353535)
 24 trial.ti. (230102)
 25 or/18-24 (1341678)
 26 13 and 25 (585)
 27 17 or 26 (687)
 28 exp Animals/ not Humans/ (4739090)
 29 (news or editorial or case report).pt. or case report.ti. (1008198)
 30 27 not (28 or 29) (664)
 31 remove duplicates from 30 (653)

A.2: Source: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily

Interface / URL: Ovid SP

Database coverage dates: 1946 to 02/10/2020

Search date: 08/10/2020

Retrieved records: 320

Search strategy:

Note: This strategy identified economic studies and studies on lost productivity.

1 Skin Diseases, Eczematous/ (69)
 2 Eczema/ (10998)
 3 Eczema, Dyshidrotic/ (282)
 4 exp Dermatitis, Contact/ (34116)
 5 (eczema\$ or dermatos\$ or dermatit\$.ti,ab,kf. (92408)
 6 (dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite).ti,ab,kf. (2117)
 7 or/1-6 (111678)
 8 exp Hand/ (79492)
 9 (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits
 or finger or fingers or nail or nails).ti,ab,kf. (579808)
 10 or/8-9 (605744)
 11 7 and 10 (6793)
 12 Hand Dermatoses/ (7717)
 13 or/11-12 (12570)
 14 Economics/ (27238)
 15 exp "Costs and cost analysis"/ (238804)
 16 Economics, dental/ (1911)
 17 exp "Economics, hospital"/ (24702)

18 Economics, medical/ (9100)
 19 Economics, nursing/ (3999)
 20 Economics, pharmaceutical/ (2955)
 21 (economic\$ or cost or costs or costly or costing or price or prices or pricing or
 pharmaco-economic\$.ti,ab. (832623)
 22 (expenditure\$ not energy).ti,ab. (30990)
 23 value for money.ti,ab. (1760)
 24 budget\$.ti,ab. (30288)
 25 or/14-24 (986100)
 26 ((energy or oxygen) adj cost).ti,ab. (4184)
 27 (metabolic adj cost).ti,ab. (1466)
 28 ((energy or oxygen) adj expenditure).ti,ab. (25795)
 29 or/26-28 (30453)
 30 25 not 29 (979129)
 31 Absenteeism/ (9102)
 32 Presenteeism/ (314)
 33 (absenteeism or presenteeism).ti,ab,kf. (6708)
 34 ((sickness or illness) adj presence).ti,ab,kf. (115)
 35 Sick Leave/ (5864)
 36 ((sick\$ or illness or disabilit\$) adj3 (leave\$ or absen\$ or rate\$)).ti,ab,kf. (15108)
 37 (medical\$ adj3 (leave\$ or absen\$)).ti,ab,kf. (1803)
 38 ((day\$ or week\$ or month\$ or year\$ or time or duration) adj3 (sick\$ or absen\$ or illness\$ or
 disab\$)).ti,ab,kf. (38865)
 39 ((day\$ or week\$ or month\$ or year\$ or time or duration) adj3 (loss\$ or lost or losing)).ti,ab,kf.
 (43926)
 40 ((day\$ or week\$ or month\$ or year\$ or time or duration) adj (away or off)).ti,ab,kf. (6199)
 41 (sicklist\$ or sick-list\$).ti,ab,kf. (708)
 42 (productiv\$ or unproductiv\$).ti,ab,kf. (99114)
 43 or/31-42 (205777)
 44 13 and (30 or 43) (333)
 45 exp Animals/ not Humans/ (4739090)
 46 (news or editorial or case report).pt. or case report.ti. (1008198)
 47 44 not (45 or 46) (325)
 48 remove duplicates from 47 (320)

A.3: Source: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily

Interface / URL: Ovid SP

Database coverage dates: 1946 to 02/10/2020

Search date: 08/10/2020

Retrieved records: 179

Search strategy:

Note: This strategy identified studies of utility elicitation for chronic hand eczema.

1 Skin Diseases, Eczematous/ (69)
 2 Eczema/ (10998)
 3 Eczema, Dyshidrotic/ (282)

4 exp Dermatitis, Contact/ (34116)
5 (eczema\$ or dermatos\$ or dermatit\$).ti,ab,kf. (92408)
6 (dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite).ti,ab,kf. (2117)
7 or/1-6 (111678)
8 exp Hand/ (79492)
9 (hand or hands or palm or palms or palmar or palmopltantar or acra or acral or acras or digit or digits
or finger or fingers or nail or nails).ti,ab,kf. (579808)
10 or/8-9 (605744)
11 7 and 10 (6793)
12 Hand Dermatoses/ (7717)
13 or/11-12 (12570)
14 Quality-Adjusted Life Years/ (12497)
15 (quality adjusted or adjusted life year\$).ti,ab,kf. (17714)
16 (qaly\$ or qald\$ or qale\$ or qtime\$).ti,ab,kf. (11290)
17 (illness state\$1 or health state\$1).ti,ab,kf. (6767)
18 (hui or hui1 or hui2 or hui3).ti,ab,kf. (1589)
19 (multiattribute\$ or multi attribute\$).ti,ab,kf. (950)
20 (utility adj3 (score\$1 or valu\$ or health\$ or cost\$ or measur\$ or disease\$ or mean or gain or gains or
index\$)).ti,ab,kf. (15953)
21 utilities.ti,ab,kf. (7505)
22 (eq-5d or eq5d or eq-5 or eq5 or euro qual or euroqual or euro qual5d or euroqual5d or euro qol or
euroqol or euro qol5d or euroqol5d or euro quol or euroquol or euro quol5d or euroquol5d or eur qol
or eurqol or eur qol5d or eur qol5d or eur?qul or eur?qul5d or euro\$ quality of life or european
qol).ti,ab,kf. (12255)
23 (euro\$ adj3 (5 d or 5d or 5 dimension\$ or 5dimension\$ or 5 domain\$ or 5domain\$)).ti,ab,kf. (4370)
24 (sf36\$ or sf 36\$ or sf thirtysix or sf thirty six).ti,ab,kf. (23179)
25 (time trade off\$1 or time tradeoff\$1 or tto or timetradeoff\$1).ti,ab,kf. (1971)
26 ((qol or hrqol or quality of life).ti,kf. or *quality of life/) and ((qol or hrqol\$ or quality of life) adj2
(increas\$ or decrease\$ or improv\$ or declin\$ or reduc\$ or high\$ or low\$ or effect or effects or worse
or score or scores or change\$1 or impact\$1 or impacted or deteriorat\$)).ab. (39952)
27 Cost-Benefit Analysis/ and (cost-effectiveness ratio\$ and (perspective\$ or life expectanc\$)).ti,ab,kf.
(3615)
28 *quality of life/ and (quality of life or qol).ti. (54543)
29 quality of life/ and ((quality of life or qol) adj3 (improv\$ or chang\$)).ti,ab,kf. (27986)
30 quality of life/ and ((quality of life or qol) adj (score\$1 or measure\$1)).ti,ab,kf. (11882)
31 quality of life/ and health-related quality of life.ti,ab,kf. (32636)
32 quality of life/ and ec.fs. (10180)
33 quality of life/ and (health adj3 status).ti,ab,kf. (9134)
34 (quality of life or qol).ti,ab,kf. and Cost-Benefit Analysis/ (12928)
35 Models, Economic/ (10239)
36 or/14-35 (171934)
37 elicitation\$1.ab,kf. or elicit\$.ti. or elicit\$.ab. /freq=2 (59220)
38 13 and (36 or 37) (195)
39 exp Animals/ not Humans/ (4739090)
40 (news or editorial or case report).pt. or case report.ti. (1008198)
41 38 not (39 or 40) (179)
42 remove duplicates from 41 (179)

A.4: Source: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily

Interface / URL: Ovid SP

Database coverage dates: 1946 to 02/10/2020

Search date: 08/10/2020

Retrieved records: 1197

Search strategy:

Note: This strategy identified cohort studies and registry studies.

- 1 Skin Diseases, Eczematous/ (69)
- 2 Eczema/ (10998)
- 3 Eczema, Dyshidrotic/ (282)
- 4 exp Dermatitis, Contact/ (34116)
- 5 (eczema\$ or dermatos\$ or dermatit\$).ti,ab,kf. (92408)
- 6 (dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite).ti,ab,kf. (2117)
- 7 or/1-6 (111678)
- 8 exp Hand/ (79492)
- 9 (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits or finger or fingers or nail or nails).ti,ab,kf. (579808)
- 10 or/8-9 (605744)
- 11 7 and 10 (6793)
- 12 Hand Dermatoses/ (7717)
- 13 or/11-12 (12570)
- 14 Cohort Studies/ (268792)
- 15 Longitudinal Studies/ (137861)
- 16 Follow-up Studies/ (647925)
- 17 Prospective Studies/ (549917)
- 18 Retrospective Studies/ (841525)
- 19 (cohort or longitudinal or prospective or retrospective).ti,kf. (363170)
- 20 or/14-19 (2149716)
- 21 Registries/ (90730)
- 22 (register or registers or registry or registries).ti,kf. (40370)
- 23 or/21-22 (103984)
- 24 13 and (20 or 23) (1221)
- 25 exp Animals/ not Humans/ (4739090)
- 26 (news or editorial or case report).pt. or case report.ti. (1008198)
- 27 24 not (25 or 26) (1203)
- 28 remove duplicates from 27 (1197)

A.5: Source: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily

Interface / URL: Ovid SP

Database coverage dates: 1946 to 02/10/2020

Search date: 08/10/2020

Retrieved records: 48

Search strategy:

Note: This strategy identified systematic reviews.

- 1 Skin Diseases, Eczematous/ (69)
- 2 Eczema/ (10998)
- 3 Eczema, Dyshidrotic/ (282)
- 4 exp Dermatitis, Contact/ (34116)
- 5 (eczema\$ or dermatos\$ or dermatit\$).ti,ab,kf. (92408)
- 6 (dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite).ti,ab,kf. (2117)
- 7 or/1-6 (111678)
- 8 exp Hand/ (79492)
- 9 (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits or finger or fingers or nail or nails).ti,ab,kf. (579808)
- 10 or/8-9 (605744)
- 11 7 and 10 (6793)
- 12 Hand Dermatoses/ (7717)
- 13 or/11-12 (12570)
- 14 (systematic adj3 review).ti,kf. (142011)
- 15 (meta-analy\$ or metaanaly\$ or meta-synthes\$ or metasynthes\$ or meta-regressi\$ or metaregressi\$).ti,kf. (126540)
- 16 systematic overview\$.ti,kf. (296)
- 17 or/14-16 (214692)
- 18 13 and 17 (50)
- 19 exp Animals/ not Humans/ (4739090)
- 20 (news or editorial or case report).pt. or case report.ti. (1008198)
- 21 18 not (19 or 20) (48)
- 22 remove duplicates from 21 (48)

A.6: Source: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily

Interface / URL: Ovid SP

Database coverage dates: 1946 to 02/10/2020

Search date: 08/10/2020

Retrieved records: 428

Search strategy:

Note: This strategy identified cost of illness, economic and cost studies.

- 1 Skin Diseases, Eczematous/ (69)
- 2 Eczema/ (10998)
- 3 Eczema, Dyshidrotic/ (282)
- 4 exp Dermatitis, Contact/ (34116)
- 5 (eczema\$ or dermatos\$ or dermatit\$).ti,ab,kf. (92408)
- 6 (dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite).ti,ab,kf. (2117)
- 7 or/1-6 (111678)
- 8 exp Hand/ (79492)
- 9 (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits or finger or fingers or nail or nails).ti,ab,kf. (579808)
- 10 or/8-9 (605744)

11 7 and 10 (6793)
 12 Hand Dermatoses/ (7717)
 13 or/11-12 (12570)
 14 "Cost of Illness"/ (27572)
 15 ((burden or cost) adj3 (illness or disease)).ti,ab,kf. (37998)
 16 exp Healthcare Costs/ (65896)
 17 "Costs and Cost Analysis"/ (48876)
 18 Cost-Benefit Analysis/ (81902)
 19 (cost or costs).ti,ab,kf. (576085)
 20 (costing adj3 (illness\$ or disease\$ or sickness\$ or treatment\$ or therap\$)).ti,ab,kf. (142)
 21 (burden\$1 adj3 (illness\$ or disease\$ or sickness\$ or treatment\$ or therap\$)).ti,ab,kf. (41067)
 22 (resource\$1 adj4 (use\$1 or usage or utilit\$)).ti,ab,kf. (32990)
 23 (economic evaluation\$ or pharmacoeconomic\$).ti,ab,kf. (16779)
 24 (hospitalization\$1 or hospitalisation\$1 or hospitalised or hospitalized).ti,ab,kf. (256487)
 25 (admission\$1 or readmission\$1 or admitted or readmitted or visit or visits).ti,ab,kf. (584742)
 26 (bed adj2 days).ti,ab,kf. (2686)
 27 hospital stay\$1.ti,ab,kf. (87249)
 28 ((days or time or length or duration\$1) adj3 hospital\$).ti,ab,kf. (94861)
 29 ((days or time or length or duration\$1) adj3 (stay or stays or stayed)).ti,ab,kf. (106540)
 30 ((days or time or length or duration\$1) adj3 (discharge or discharged or home or homes)).ti,ab,kf.
 (24882)
 31 or/14-30 (1502441)
 32 13 and 31 (455)
 33 exp Animals/ not Humans/ (4739090)
 34 (news or editorial or case report).pt. or case report.ti. (1008198)
 35 32 not (33 or 34) (436)
 36 remove duplicates from 35 (428)

A.7: Source: Embase

Interface / URL: OvidSP

Database coverage dates: 1974 to 2020 October 09

Search date: 12/10/2020

Retrieved records: 1564

Search strategy:

Note: This strategy identified RCTs and patient preference studies.

1 exp dermatitis/ (154159)
 2 (eczema\$ or dermatos\$ or dermatit\$).ti,ab,kw. (118915)
 3 (dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite).ti,ab,kw. (2002)
 4 or/1-3 (189977)
 5 exp hand/ (80092)
 6 (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits
 or finger or fingers or nail or nails).ti,ab,kw. (747697)
 7 or/5-6 (768128)
 8 4 and 7 (12475)
 9 Randomized controlled trial/ (624974)

10 Controlled clinical study/ (465160)
11 Random\$.ti,ab. (1586530)
12 randomization/ (88500)
13 intermethod comparison/ (265947)
14 placebo.ti,ab. (312364)
15 (compare or compared or comparison).ti. (521081)
16 ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing
or comparison)).ab. (2185268)
17 (open adj label).ti,ab. (82059)
18 ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab. (236634)
19 double blind procedure/ (176874)
20 parallel group\$1.ti,ab. (26225)
21 (crossover or cross over).ti,ab. (107391)
22 ((assign\$ or match or matched or allocation) adj5 (alternate or group\$1 or intervention\$1 or patient\$1
or subject\$1 or participant\$1)).ti,ab. (339243)
23 (assigned or allocated).ti,ab. (399884)
24 (controlled adj7 (study or design or trial)).ti,ab. (359826)
25 (volunteer or volunteers).ti,ab. (251995)
26 human experiment/ (518865)
27 trial.ti. (311282)
28 or/9-27 (5163458)
29 (random\$ adj sampl\$ adj7 ("cross section\$" or questionnaire\$1 or survey\$ or database\$1)).ti,ab. not
(comparative study/ or controlled study/ or randomi?ed controlled.ti,ab. or randomly assigned.ti,ab.)
(8257)
30 Cross-sectional study/ not (randomized controlled trial/ or controlled clinical study/ or controlled
study/ or randomi?ed controlled.ti,ab. or control group\$1.ti,ab.) (249251)
31 (((case adj control\$) and random\$) not randomi?ed controlled).ti,ab. (17691)
32 (Systematic review not (trial or study)).ti. (155173)
33 (nonrandom\$ not random\$).ti,ab. (16477)
34 "Random field\$.ti,ab. (2422)
35 (random cluster adj3 sampl\$).ti,ab. (1312)
36 (review.ab. and review.pt.) not trial.ti. (834747)
37 "we searched".ab. and (review.ti. or review.pt.) (33585)
38 "update review".ab. (110)
39 (databases adj4 searched).ab. (38228)
40 (rat or rats or mouse or mice or swine or porcine or murine or sheep or lambs or pigs or piglets or
rabbit or rabbits or cat or cats or dog or dogs or cattle or bovine or monkey or monkeys or trout or
marmoset\$1).ti. and animal experiment/ (1082614)
41 Animal experiment/ not (human experiment/ or human/) (2280357)
42 or/29-41 (3561433)
43 28 not 42 (4593091)
44 8 and 43 (1494)
45 patient preference/ (19170)
46 prefer\$.ti,ab,kw. (578823)
47 8 and (45 or 46) (178)
48 (animal/ or animal experiment/ or animal model/ or animal tissue/ or nonhuman/) not exp human/
(6111578)
49 editorial.pt. or case report.ti. (969478)

- 50 (44 or 47) not (48 or 49) (1582)
51 remove duplicates from 50 (1564)

A.8: Source: Embase

Interface / URL: OvidSP

Database coverage dates: Embase 1974 to 2020 October 12

Search date: 13/10/2020

Retrieved records: 542

Search strategy:

Note: This strategy identified economic studies and studies on lost productivity.

- 1 exp dermatitis/ (154217)
2 (eczema\$ or dermatos\$ or dermatit\$).ti,ab,kw. (118988)
3 (dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite).ti,ab,kw. (2004)
4 or/1-3 (190057)
5 exp hand/ (80133)
6 (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits
or finger or fingers or nail or nails).ti,ab,kw. (748027)
7 or/5-6 (768461)
8 4 and 7 (12484)
9 Health Economics/ (33077)
10 exp Economic Evaluation/ (310155)
11 exp Healthcare Cost/ (294817)
12 pharmacoeconomics/ (7396)
13 (econom\$ or cost or costs or costly or costing or price or prices or pricing or
pharmacoeconomic\$).ti,ab. (1096269)
14 (expenditure\$ not energy).ti,ab. (41294)
15 (value adj2 money).ti,ab. (2483)
16 budget\$.ti,ab. (39353)
17 or/9-16 (1358887)
18 (metabolic adj cost).ti,ab. (1553)
19 ((energy or oxygen) adj cost).ti,ab. (4404)
20 ((energy or oxygen) adj expenditure).ti,ab. (32240)
21 or/18-20 (37083)
22 17 not 21 (1351275)
23 absenteeism/ (17467)
24 presenteeism/ (1367)
25 (absenteeism or presenteeism).ti,ab,kw. (9359)
26 ((sickness or illness) adj presence).ti,ab,kw. (161)
27 medical leave/ (6861)
28 ((sick\$ or illness or disabilit\$) adj3 (leave\$ or absen\$ or rate\$)).ti,ab,kw. (19572)
29 (medical\$ adj3 (leave\$ or absen\$)).ti,ab,kw. (2465)
30 ((day\$ or week\$ or month\$ or year\$ or time or duration) adj3 (sick\$ or absen\$ or illness\$ or
disab\$)).ti,ab,kw. (55315)
31 ((day\$ or week\$ or month\$ or year\$ or time or duration) adj3 (loss\$ or lost or losing)).ti,ab,kw.
(65406)
32 ((day\$ or week\$ or month\$ or year\$ or time or duration) adj (away or off)).ti,ab,kw. (10414)

33 (sicklist\$ or sick-list\$).ti,ab,kw. (767)
34 (productiv\$ or unproductiv\$).ti,ab,kw. (118282)
35 or/23-34 (271821)
36 8 and (22 or 35) (575)
37 (animal/ or animal experiment/ or animal model/ or animal tissue/ or nonhuman/) not exp human/
(6113634)
38 editorial.pt. or case report.ti. (970037)
39 36 not (37 or 38) (551)
40 remove duplicates from 39 (542)

A.9: Source: Embase

Interface / URL: OvidSP

Database coverage dates: Embase 1974 to 2020 October 12

Search date: 13/10/2020

Retrieved records: 319

Search strategy:

Note: This strategy identified studies of utility elicitation for chronic hand eczema.

1 exp dermatitis/ (154217)
2 (eczema\$ or dermatos\$ or dermatit\$).ti,ab,kw. (118988)
3 (dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite).ti,ab,kw. (2004)
4 or/1-3 (190057)
5 exp hand/ (80133)
6 (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits
or finger or fingers or nail or nails).ti,ab,kw. (748027)
7 or/5-6 (768461)
8 4 and 7 (12484)
9 quality adjusted life year/ (27362)
10 (quality adjusted or adjusted life year\$).ti,ab,kw. (25782)
11 (qaly\$ or qald\$ or qale\$ or qtime\$).ti,ab,kw. (21023)
12 (illness state\$1 or health state\$1).ti,ab,kw. (11622)
13 (hui or hui1 or hui2 or hui3).ti,ab,kw. (2378)
14 (multiattribute\$ or multi attribute\$).ti,ab,kw. (1206)
15 (utility adj3 (score\$1 or valu\$ or health\$ or cost\$ or measur\$ or disease\$ or mean or gain or gains or
index\$)).ti,ab,kw. (25087)
16 utilities.ti,ab,kw. (12091)
17 (eq-5d or eq5d or eq-5 or eq5 or euro qual or euroqual or euro qual5d or euroqual5d or euro qol or
euroqol or euro qol5d or euroqol5d or euro quol or euroquol or euro quol5d or euroquol5d or eur qol
or eurqol or eur qol5d or eur qol5d or eur?qul or eur?qul5d or euro\$ quality of life or european
qol).ti,ab,kw. (22095)
18 (euro\$ adj3 (5 d or 5d or 5 dimension\$ or 5dimension\$ or 5 domain\$ or 5domain\$)).ti,ab,kw. (6540)
19 (sf36\$ or sf 36\$ or sf thirtysix or sf thirty six).ti,ab,kw. (38751)
20 (time trade off\$1 or time tradeoff\$1 or tto or timetradeoff\$1).ti,ab,kw. (2854)
21 ((qol or hrqol or quality of life).ti,kw. or *"quality of life"/) and ((qol or hrqol\$ or quality of life) adj2
(increas\$ or decrease\$ or improv\$ or declin\$ or reduc\$ or high\$ or low\$ or effect or effects or worse
or score or scores or change\$1 or impact\$1 or impacted or deteriorat\$)).ab. (58989)

22 "cost-benefit analysis"/ and (cost-effectiveness ratio\$ and (perspective\$ or life expectanc\$)).ti,ab,kw. (855)

23 *"quality of life"/ and (quality of life or qol).ti. (87921)

24 "quality of life"/ and ((quality of life or qol) adj3 (improv\$ or chang\$)).ti,ab,kw. (77904)

25 "quality of life"/ and ((quality of life or qol) adj (score\$1 or measure\$1)).ti,ab,kw. (26133)

26 "quality of life"/ and health-related quality of life.ti,ab,kw. (60028)

27 "quality of life"/ and pe.fs. (8528)

28 "quality of life"/ and (health adj3 status).ti,ab,kw. (16592)

29 (quality of life or qol).ti,ab,kw. and "cost-benefit analysis"/ (5612)

30 economic model/ (2180)

31 or/9-30 (291772)

32 elicitation\$1.ab,kw. or elicit\$.ti. or elicit\$.ab. /freq=2 (68066)

33 8 and (31 or 32) (341)

34 (animal/ or animal experiment/ or animal model/ or animal tissue/ or nonhuman/) not exp human/ (6113634)

35 editorial.pt. or case report.ti. (970037)

36 33 not (34 or 35) (323)

37 remove duplicates from 36 (319)

Search note: For the 2018 search, line 27 was: "quality of life"/ and ec.fs. In Embase the syntax *ec* is used for Endogenous Compound – the inclusion of *ec* as a floating subheading was incorrect. The syntax relating to economics is *pe* for Pharmacoeconomics. For the 2020 update search, the previously used *ec* was replaced with *pe*.

A.10: Source: Embase

Interface / URL: OvidSP

Database coverage dates: 1974 to 2020 October 09

Search date: 12/10/2020

Retrieved records: 1541

Search strategy:

Note: This strategy identified cohort studies and registry studies.

1 exp dermatitis/ (154159)

2 (eczema\$ or dermatos\$ or dermatit\$).ti,ab,kw. (118915)

3 (dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite).ti,ab,kw. (2002)

4 or/1-3 (189977)

5 exp hand/ (80092)

6 (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits or finger or fingers or nail or nails).ti,ab,kw. (747697)

7 or/5-6 (768128)

8 4 and 7 (12475)

9 cohort analysis/ (623417)

10 longitudinal study/ (145888)

11 follow-up/ (1594421)

12 prospective study/ (633140)

13 retrospective study/ (974268)

14 (cohort or longitudinal or prospective or retrospective).ti,kw. (511771)

15 or/9-14 (3299606)
16 register/ (114343)
17 (register or registers or registry or registries).ti,kw. (68195)
18 or/16-17 (151157)
19 8 and (15 or 18) (1624)
20 (animal/ or animal experiment/ or animal model/ or animal tissue/ or nonhuman/) not exp human/
(6111578)
21 editorial.pt. or case report.ti. (969478)
22 19 not (20 or 21) (1560)
23 remove duplicates from 22 (1541)

A.11: Source: Embase

Interface / URL: OvidSP

Database coverage dates: 1974 to 2020 October 12

Search date: 13/10/2020

Retrieved records: 84

Search strategy:

Note: This strategy identified systematic reviews.

1 exp dermatitis/ (154217)
2 (eczema\$ or dermatos\$ or dermatit\$.ti,ab,kw. (118988)
3 (dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite).ti,ab,kw. (2004)
4 or/1-3 (190057)
5 exp hand/ (80133)
6 (hand or hands or palm or palms or palmar or palmopltantar or acra or acral or acras or digit or digits
or finger or fingers or nail or nails).ti,ab,kw. (748027)
7 or/5-6 (768461)
8 4 and 7 (12484)
9 (systematic adj3 review).ti,kw. (170930)
10 (meta-analy\$ or metaanaly\$ or meta-synthes\$ or metasynthes\$ or meta-regressi\$ or
metaregressi\$.ti,kw. (161064)
11 systematic overview\$.ti,kw. (336)
12 or/9-11 (264491)
13 8 and 12 (86)
14 (animal/ or animal experiment/ or animal model/ or animal tissue/ or nonhuman/) not exp human/
(6113634)
15 editorial.pt. or case report.ti. (970037)
16 13 not (14 or 15) (84)
17 remove duplicates from 16 (84)

A.12: Source: Embase

Interface / URL: OvidSP

Database coverage dates: 1974 to 2020 October 09

Search date: 12/10/2020

Retrieved records: 919

Search strategy:

Note: This strategy identified cost of illness studies, economic and cost studies.

1 exp dermatitis/ (154159)
2 (eczema\$ or dermatos\$ or dermatit\$).ti,ab,kw. (118915)
3 (dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite).ti,ab,kw. (2002)
4 or/1-3 (189977)
5 exp hand/ (80092)
6 (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits
or finger or fingers or nail or nails).ti,ab,kw. (747697)
7 or/5-6 (768128)
8 4 and 7 (12475)
9 "cost of illness"/ (19456)
10 ((burden or cost) adj3 (illness or disease)).ti,ab,kw. (57387)
11 exp healthcare cost/ (294776)
12 cost/ (58780)
13 cost benefit analysis/ (85387)
14 (cost or costs).ti,ab,kw. (764630)
15 (costing adj3 (illness\$ or disease\$ or sickness\$ or treatment\$ or therap\$)).ti,ab,kw. (223)
16 (burden\$1 adj3 (illness\$ or disease\$ or sickness\$ or treatment\$ or therap\$)).ti,ab,kw. (62066)
17 (resource\$1 adj4 (use\$1 or usage or utilit\$)).ti,ab,kw. (45459)
18 (economic evaluation\$ or pharmaco-economic\$).ti,ab,kw. (26563)
19 (hospitalization\$1 or hospitalisation\$1 or hospitalised or hospitalized).ti,ab,kw. (407865)
20 (admission\$1 or readmission\$1 or admitted or readmitted or visit or visits).ti,ab,kw. (959229)
21 (bed adj2 days).ti,ab,kw. (4403)
22 hospital stay\$1.ti,ab,kw. (140768)
23 ((days or time or length or duration\$1) adj3 hospital\$).ti,ab,kw. (156365)
24 ((days or time or length or duration\$1) adj3 (stay or stays or stayed)).ti,ab,kw. (185603)
25 ((days or time or length or duration\$1) adj3 (discharge or discharged or home or homes)).ti,ab,kw.
(43882)
26 or/9-25 (2316651)
27 8 and 26 (1008)
28 (animal/ or animal experiment/ or animal model/ or animal tissue/ or nonhuman/) not exp human/
(6111578)
29 editorial.pt. or case report.ti. (969478)
30 27 not (28 or 29) (933)
31 remove duplicates from 30 (919)

A.13: Source: NHS Economic Evaluation Database (NHS EED)

Interface / URL: <https://www.crd.york.ac.uk/CRDWeb/>

Database coverage dates: Information not found. Bibliographic records were published on NHS EED until 31st March 2015. Searches of MEDLINE, Embase, CINAHL, PsycINFO and PubMed were continued until the end of the 2014.

Search date: 14/10/2020

Retrieved records: 10

Search strategy:

1 MeSH DESCRIPTOR Skin Diseases, Eczematous 0
2 MeSH DESCRIPTOR Eczema 26

3 MeSH DESCRIPTOR Eczema, Dyshidrotic 0
 4 MeSH DESCRIPTOR Dermatitis, Contact EXPLODE ALL TREES 14
 5 ((eczema* OR dermatos* OR dermatit*)) 288
 6 ((dyshidro* OR dyshydro* OR dishidro* OR dishydro* OR pulpitis OR pulpite)) 15
 7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6) 303
 8 MeSH DESCRIPTOR Hand EXPLODE ALL TREES 72
 9 ((hand OR hands OR palm OR palms OR palmar OR palmoplantar OR acra OR acral OR acras OR
 digit OR digits OR finger OR fingers OR nail OR nails)) 1654
 10 (#8 OR #9) 1660
 11 (#7 and #10) 32
 12 MeSH DESCRIPTOR Hand Dermatoses 11
 13 (#11 OR #12) 32
 14 (#11 OR #12) IN NHSEED 10

Search note: In 2018 NHS EED was searched via the Cochrane Library interface. NHS EED is no longer available via the Cochrane Library interface. For the 2020 update search, NHS EED was searched via the CRD interface.

A.14: Source: Cochrane Central Register of Controlled Trials (CENTRAL)

Interface / URL: Wiley / Cochrane Library

Database coverage dates: Information not found. Issue searched: Issue 10 of 12, October 2020

Search date: 14/10/2020

Retrieved records: 910

Search strategy:

#1 [mh ^"Skin Diseases, Eczematous"] 7
 #2 [mh ^Eczema] 1041
 #3 [mh ^"Eczema, Dyshidrotic"] 8
 #4 [mh "Dermatitis, Contact"] 747
 #5 (eczema* or dermatos* or dermatit*) 11269
 #6 (dyshidro* or dyshydro* or dishidro* or dishydro* or pulpitis or pulpite) 834
 #7 #1 or #2 or #3 or #4 or #5 or #6 12079
 #8 [mh Hand] 2292
 #9 (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits
 or finger or fingers or nail or nails) 49739
 #10 #8 or #9 49814
 #11 #7 and #10 1141
 #12 [mh ^"Hand Dermatoses"] 257
 #13 #11 or #12 1141
 #14 #11 or #12 in Trials 910

A.15: Source: HTA Database

Interface / URL: <https://database.inahta.org/>

Database coverage dates: Information not found. The former database was produced by the CRD until March 2018, at which time the addition of records was stopped as INAHTA was in the process of rebuilding the new database platform. In July 2019, the database records were exported from the CRD platform and imported into the new platform that was developed by INAHTA. The rebuild of the new platform was launched in June 2020.

Search date: 14/10/2020

Retrieved records: 2

Search strategy:

11	#10 AND #7	2
10	#9 OR #8	228
9	(hand OR hands OR palm OR palms OR palmar OR palmoplantar OR acra OR acral OR acras OR digit OR digits OR finger OR fingers OR nail OR nails)	223
8	"Hand"[mhe]	19
7	#6 OR #5 OR #4 OR #3 OR #2 OR #1	35
6	(dyshidro* OR dyshydro* OR dishidro* OR dishydro* OR pulpitis OR pulpite)	1
5	(eczema* OR dermatos* OR dermatit*)	34
4	"Dermatitis, Contact"[mhe]	0
3	"Eczema, Dyshidrotic"[mh]	0
2	"Eczema"[mh]	6
1	"Skin Diseases, Eczematous"[mh]	0

Search note: In 2018 the HTA database was searched via the University of York Centre for Reviews and Dissemination (CRD) interface. This version of the HTA is no longer being updated (from the 31 March 2018, the HTA database has remained available, but CRD are no longer adding new records to it). A new version of the HTA database is now available via INAHTA. For the 2020 update search, the new INAHTA HTA Database was searched.

A.16: Source: Cost-Effectiveness Analysis (CEA) Registry

Interface / URL: <http://healtheconomicsdev.tuftsmedicalcenter.org/cear2/search/search.aspx>

Database coverage dates: The website states that the database includes studies published from 1976 to 2018 (<https://cevr.tuftsmedicalcenter.org/databases/cea-registry>). However, more recent studies (e.g. 2019 and 2020) can be found in the database.

Search date: 14/10/2020

Retrieved records: 4

Search strategy:

The search interface at the above URL was used. The following terms were searched separately.

Records for downloaded results were retrieved via PubMed.

hand eczema = 3 (3 results returned, 3 results downloaded)

hand dermatitis = 1 results (2 results returned: 1 excluded as duplicate, 1 downloaded)

hand dermatosis = 0 results

hand dermatose = 0 results

dyshidrosis = 0 results

dyshidroses = 0 results

dyshydrosis = 0 results

dyshydroses = 0 results

dishidrosis = 0 results

dishidroses = 0 results

dishydrosis = 0 results

dishydroses = 0 results

pulpitis = 0 results

pulpite = 0 results

A.17: Source: ScHARRHUD

Interface / URL: <https://www.scharrhud.org/>

Database coverage dates: Information not found

Search date: 14/10/2020

Retrieved records: 0

Search strategy:

The search was conducted using the search interface at:

<https://www.scharrhud.org/index.php?recordsN1&m=search>

The following terms were entered. The drop-down field options were left at default ('Any field'). The two sets of terms were combined with Boolean AND using the drop-down option.

(eczema* or dermatos* or dermatit* or dyshidro* or dyshydro* or dishidro* or dishydro* or pulpitis or pulpite)

AND

(hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits or finger or fingers or nail or nails)

0 records were returned

A.18: Source: Evidence Search

Interface / URL: <https://www.evidence.nhs.uk/>

Database coverage dates: Information not found

Search date: 14/10/2020

Retrieved records: 418

Search strategy:

The following search terms were entered in to the search interface at:

(eczema or dermatosis or dermatitis) AND (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits or finger or fingers or nail or nails or dyshidrosis or dyshidrotic or pulpitis or pulpite)

(eczema OR dermatosis OR dermatitis) AND (hand OR hands OR palm OR palms OR palmar OR palmoplantar OR acra OR acral OR acras OR digit OR digits OR finger OR fingers OR nail OR nails OR dyshidrosis OR dyshidrotic OR pulpitis OR pulpite)

1028 results were returned. Results were restricted using the 'Filter' options available to Guidance and Policy. In the information under the filter, the interface indicated that 653 results were returned when applying this restriction. However, in the information above the search results, the interface indicated that 418 results were returned. The search was re-run a number of times by two Information Specialists with the same outcome. An e-mail query was sent to NICE questioning the difference between the two result numbers. NICE confirmed that the difference is due to the way the interface rolls up certain types of results into one result, and that 418 was the correct number of unique results that could be downloaded when the search was restricted using the 'Filter' options available to Guidance and Policy.

418 is the number of records retrieved.

A.19: Source: National Institute for Health and Care Excellence (NICE) website

Interface / URL: <https://www.nice.org.uk>

Database coverage dates: n/a

Search date: 16/10/2020

Retrieved records: 0

Search strategy:

The previous search was conducted on 04/07/18.

The default search interface was used at the above URL. The following terms were searched on separately. Results were assessed by the Information Specialist for guidelines focused on the population of interest - chronic hand eczema – with a publication date of 04/07/18 to date. Relevant company submission documents or guidance documents were retrieved.

(eczema or dermatosis or dermatitis) AND (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits or finger or fingers or nail or nails or dyshidrosis or dyshidrotic or pulpitis or pulpitis) = 0 (7 results returned)

0 documents were retrieved for further assessment

A.20: Source: Guidelines International Network International Guideline Library

Interface / URL: <https://guidelines.ebmportal.com/>

Database coverage dates: Information not found

Search date: 16/10/2020

Retrieved records: 0

Search strategy:

The previous search was conducted on 04/07/18.

The default search interface was used at the above URL. The following terms were searched on separately. Results were assessed by the Information Specialist for guidelines focused on the population of interest - chronic hand eczema – with a publication date or expected publication date of 04/07/18 to date. Duplicates were excluded. For any potentially relevant guideline result, the full text online was sought via the link provided in the Library. Published guidelines were retrieved.

eczema = 0 (5 results returned)

dermatosis = 0 (1 result returned)

dermatitis = 0 (6 results returned)

0 guidelines were retrieved for further consideration.

Search note: In 2018 the search URL used for the Guidelines International Network International Guideline Library was <http://www.g-i-n.net/library/international-guidelines-library/>. This URL no longer leads to a search interface. For the 2020 update search, the following URL was used: <https://guidelines.ebmportal.com/>

A.21: Source: ECRI Guidelines Trust

Interface / URL: <https://www.ecri.org/solutions/ecri-guidelines-trust>

Database coverage dates:

Search date: 16/10/2020

Retrieved records: 0

Search strategy:

The previous search was conducted on 04/07/18.

The Information Specialist logged into the ECRI Guidelines Trust at the above URL using username and password.

The default search interface was used. The following terms were searched on separately. Results were assessed by the Information Specialist for guidelines focused on the population of interest - chronic hand eczema – with a publication date of 04/07/18 to date. Duplicates were excluded.

eczema = 0 (4 results returned)

dermatosis = 0 (1 result returned)

dermatitis = 0 (21 results returned)

0 guidelines were retrieved for further assessment

Search note: In 2018 the National Guideline Clearinghouse was searched. This resource is no longer available. For the 2020 update search, the ECRI Guidelines Trust resource was searched as a replacement resource

A.22: Source: Office of National Statistics website

Interface / URL: <https://www.ons.gov.uk/>

Database coverage dates: n/a

Search date: 16/10/2020

Retrieved records: 0

Search strategy:

The previous search was conducted on 04/07/18

The following terms were searched on separately using the search interface at the above URL. Returned results were screened online by the Information Specialist for statistics with a publication date of 04/07/18 to date, related to chronic hand eczema disease burden (including, for example: epidemiology, incidence, prevalence, morbidity).

eczema: 0 results returned

dermatitis: 0 results returned

dermatosis: 0 results returned

dermatoses: 0 results returned

dyshidrosis: 0 results returned

pulpitis: 0 results returned

pulpite: 0 results returned

skin diseases: 0 (66 results returned)

0 results were selected for further assessment

A.23: Source: NHS Digital website

Interface / URL: <https://digital.nhs.uk/>

Database coverage dates: n/a

Search date: 14/10/2020

Retrieved records: 0

Search strategy:

The previous search was conducted on 04/07/18

The following terms were searched on separately using the search interface at the above URL. Returned results were screened online by the Information Specialist for statistics with a publication date of 04/07/18 to date, related to chronic hand eczema disease burden (including, for example: epidemiology, incidence, prevalence, morbidity).

eczema: 0 results returned
dermatitis: 0 results returned
dermatosis: 0 results returned
dermatoses: 0 results returned
dyshidrosis: 0 results returned
pulpitis: 0 results returned
pulpite: 0 results returned
skin diseases: 0 (4 results returned)

0 results were selected for further assessment

A.24: Source: Centers for Disease Control and Prevention website

Interface / URL: <https://www.cdc.gov/datastatistics/index.html>

Database coverage dates: n/a

Search date: 14/10/2020

Retrieved records: 0

Search strategy:

The previous search was conducted on 04/07/18

The advanced search interface available from the above URL was used to conduct the following searches. The searches were restricted using the 'Between these dates' option to results with a date from 04/07/18 to 16/10/20.

The information given in each returned result was scanned by the Information Specialist for potential relevance. Results judged to indicate clear potential relevance as a source of statistics related to chronic hand eczema disease burden (including, for example, epidemiology, incidence, prevalence, morbidity) were opened for further assessment. Relevant results were retrieved.

1. The following terms were entered into the search box "All these words": hand eczema = 0 (28 results returned)
2. The following terms were entered into the search box "All these words": hands eczema = 0 (28 results returned)

3. The following terms were entered into the search box "All these words": hand dermatitis = 0 (243 results returned)
4. The following terms were entered into the search box "All these words": hands dermatitis = 0 (243 results returned)
5. The following terms were entered into the search box "Any of these words" dermatosis dermatoses dyshidrosis pulpitis pulpite = 0 (55 results returned)

In addition, the webpages found under the heading 'Skin exposures and effects' in the content hierarchy on the left side of the page at the following URL were browsed by the Information Specialist for statistics with a publication date of 04/07/18 to date related to chronic hand eczema disease burden (including, for example: epidemiology, incidence, prevalence, morbidity).

<https://www.cdc.gov/niosh/topics/skin/>

0 results were retrieved for further consideration

A.25: Source: World Health Organization webpages

Interface / URL: <http://www.who.int/gho/en/>

Database coverage dates: n/a

Search date: 19/10/2020

Retrieved records: 0

Search strategy:

The previous search was conducted on 04/07/18

The following two searches were conducted.

Search 1: World Health Statistics reports were browsed for reports with a publication date of 2018 to 2020 at http://www.who.int/gho/publications/world_health_statistics/en/

The 2020 report was downloaded at: <https://apps.who.int/iris/bitstream/handle/10665/332070/9789240005105-eng.pdf>

The 2019 report was downloaded at: <https://apps.who.int/iris/bitstream/handle/10665/324835/9789241565707-eng.pdf?sequence=9&isAllowed=y>

The 2018 report was downloaded at: <https://apps.who.int/iris/bitstream/handle/10665/272596/9789241565585-eng.pdf>

The Ctrl-F function was used to search across each PDF on the following terms:

eczema
dermatitis
dermatosis
dermatoses
dyshidrosis
pulpitis
pulpite

skin

Any information found was assessed by the Information Specialist for statistics relevant to chronic hand eczema disease burden (including, for example, epidemiology, incidence, prevalence, morbidity).

No relevant statistical information was identified.

Search 2: The Global Health Observatory data repository webpage was browsed for relevant information at <http://apps.who.int/gho/data/node.home>. The information was assessed by the Information Specialist for statistics relevant to chronic hand eczema disease burden (including, for example, epidemiology, incidence, prevalence, morbidity).

No relevant statistical information was identified.

In addition, the Global Health Observatory data repository search option was used at: <https://apps.who.int/gho/data/node.imr?search=>

All 'Also search in' options were left as default (i.e. selected).

The following terms were searched on separately:

eczema = 0 results returned
dermatitis = 0 results returned
dermatosis = 0 results returned
dermatoses = 0 results returned
dyshidrosis = 0 results returned
pulpitis = 0 results returned
pulpite = 0 results returned
skin = 0 results returned

No relevant statistical information was identified.

A.26: Source: Canadian Agency for Drugs and Technologies in Health (CADTH) webpages

Interface / URL: <https://www.cadth.ca/>

Database coverage dates: n/a

Search date: 19/10/2020

Retrieved records: 9

Search strategy:

The previous search was conducted on 05/07/18.

The following documents were sought: clinical guidance, economic guidance and final recommendations.

The site-wide search interface was used at: <https://www.cadth.ca/>. Separate searches were conducted on each term shown below.

Results were filtered by 'Product Line' to "Common Drug Review".

Searches were restricted using the 'Publication Date' filter option to results with publication date from 05/07/18 to 19/10/20.

Results were assessed for potential relevance to chronic hand eczema. Relevant results were checked for document types of interest.

PDFs of relevant documents were retrieved for further assessment. Duplicate documents were not retrieved.

eczema = 9 results were returned. 9 documents were downloaded related to three Common Drug Review reports

dermatitis = 6 results were returned. 0 documents were downloaded

dermatosis = 0 results were returned

dermatoses = 0 results were returned

dyshidrosis = 0 results were returned

pulpitis = 0 results were returned

pulpite = 0 results were returned

9 documents were retrieved for further assessment

A.27: Source: Institute for Quality and Efficiency in Healthcare (IQWiG) webpages

Interface / URL: <https://www.iqwig.de/en/projects-results/projects.1057.html>

Database coverage dates: n/a

Search date: 19/10/2020

Retrieved records: 3

Search strategy:

The previous search was conducted on 05/07/18.

The following documents were sought: dossier assessment documents (German language) and accompanying "extract of dossier assessment" documents in English (if available).

The "Projects" search engine was used, found at: <https://www.iqwig.de/en/projects-results/projects.1057.html>

"Drug Assessment" was selected from the "Department/Division" menu

Separate searches were conducted on each term shown below. The term was entered and "Filter Projects" was selected to see the results.

Results were checked for potential relevance to hand eczema, published from 05/07/18 to date. For relevant results, the "Report documents" link was selected to view the PDF files available to download. The files were checked to identify the dossier assessment documents (German language) and accompanying "extract of dossier assessment" documents in English (if available).

PDFs of relevant documents were retrieved for further assessment. If a relevant additional result was shown for the Benefit Assessment or an additional Addendum, these were also saved as PDF files.

eczema = 0 retrieved (1 result returned)

dermatitis = 3 documents retrieved (3 results returned)

dermatosis = 0 results returned
dermatoses = 0 results returned
dyshidrosis = 0 results returned
pulpitis = 0 results returned
pulpite = 0 results returned

3 documents were retrieved

A.28: Source: MEDLINE(R) ALL

Interface / URL: OvidSP

Database coverage dates: 1946 to October 27, 2020

Search date: 29/10/2020

Retrieved records: 601

Search strategy:

- 1 Skin Diseases, Eczematous/ep, mo (4)
- 2 Skin Diseases, Eczematous/ and (epidemiology/ or incidence/ or prevalence/ or exp mortality/ or morbidity/ or exp comorbidity/) (3)
- 3 Eczema/ep, mo (1281)
- 4 Eczema/ and (epidemiology/ or incidence/ or prevalence/ or exp mortality/ or morbidity/ or exp comorbidity/) (783)
- 5 Eczema, Dyshidrotic/ep, mo (11)
- 6 Eczema, Dyshidrotic/ and (epidemiology/ or incidence/ or prevalence/ or exp mortality/ or morbidity/ or exp comorbidity/) (8)
- 7 exp Dermatitis, Contact/ep, mo (3112)
- 8 exp Dermatitis, Contact/ and (epidemiology/ or incidence/ or prevalence/ or exp mortality/ or morbidity/ or exp comorbidity/) (1323)
- 9 ((eczema\$ or dermatos\$ or dermatit\$) and (epidemiolog\$ or incidence or incidences or incident or incidents or prevalen\$ or mortalit\$ or morbidit\$ or comorbidit\$ or multimorbidit\$)).ti. (1223)
- 10 ((dyshidro\$ or dyshydro\$ or dishidro\$ or dishydro\$ or pulpitis or pulpite) and (epidemiolog\$ or incidence or incidences or incident or incidents or prevalen\$ or mortalit\$ or morbidit\$ or comorbidit\$ or multimorbidit\$)).ti. (7)
- 11 or/1-10 (5279)
- 12 exp Hand/ (79730)
- 13 (hand or hands or palm or palms or palmar or palmoplantar or acra or acral or acras or digit or digits or finger or fingers or nail or nails).ti. (100978)
- 14 or/12-13 (148440)
- 15 11 and 14 (345)
- 16 Hand Dermatoses/ep, mo (723)
- 17 Hand Dermatoses/ and (epidemiology/ or incidence/ or prevalence/ or exp mortality/ or morbidity/ or exp comorbidity/) (430)
- 18 Hand Dermatoses/ and (epidemiolog\$ or incidence or incidences or incident or incidents or prevalen\$ or mortalit\$ or morbidit\$ or comorbidit\$ or multimorbidit\$).ti. (178)
- 19 or/16-18 (841)
- 20 15 or 19 (910)
- 21 exp Animals/ not Humans/ (4749702)
- 22 (news or editorial or case report).pt. or case report.ti. (992605)
- 23 20 not (21 or 22) (900)

24 limit 23 to yr="2000 -Current" (601)

Search note: For the 2020 update search, this additional, targeted, pragmatic search for records explicitly referring to chronic hand eczema epidemiology (non-specific epidemiology, incidence, prevalence, mortality, morbidity, comorbidity or multimorbidity) was conducted. This search was not conducted for the original 2018 search.

Online Resource 2 – Quality Assessment Tables

Table S1. Risk of bias assessment of cost studies

Study	Selection of participants – was there clear inclusion and exclusion criteria?	How representative of the target population were the participants in the study, considering age, disease severity, co-morbidities?	Were the data collection methods reasonable/valid?	Have the researchers tried to reduce potentials for bias, for example interviewer bias?	Have the researchers offered assessments of the limitations of the study approach?
Cortesi, 2014 [6]	Partly - inclusion criteria reported	Representative	Yes - outlined in detail using a variety of methods	No	Yes - methodology to estimate indirect costs, applicability of results to other countries.
Fowler, 2006 [7]	No - no details of study population given, only stated it was chronic hand eczema	Not clear	Yes - taken from a survey of patients in a health plan	NA	Yes - survey response rate was low, respondents may not be representative, cost burden underestimated as no indirect costs or over the counter drugs, multivariate models had low goodness of fit
Diepgen, 2013 [11]	No - published elsewhere	Representative	Yes - taken from 2 surveys	No	Partly - transferability issues reported
Petersen, 2014 [22]	Partly - limited details on inclusion criteria were reported	Representative	Yes	NA	Partly - bias due to higher dropout rate for men, investigators did not assess severity
Augustin, 2011 [10]	Yes	Representative	Yes	No	No

Table S2. Risk of bias assessment of economic models (NICE cost-effectiveness checklist, adapted from Drummond, 1996 [1])

Question		Study	
		Van Gils, 2013 [12]	NICE TA177, 2008 [8]
1. Was the research question stated?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement		
2. Was the economic importance of the research question stated?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement		
3. Was/were the viewpoint(s) of the analysis clearly stated and justified?	Yes / No / Not clear / NA	Yes	Yes
	6. Was the form of economic evaluation stated? Comment - provide brief justification for judgement	Societal	NHS
4. Was a rationale reported for the choice of the alternative programmes or interventions compared?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement		According to the patients' population considered
5. Were the alternatives being compared clearly described?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement	Detailed description	
6. Was the form of economic evaluation stated?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement	CUA	CUA
7. Was the choice of form of economic evaluation justified in relation to the questions addressed?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement	Impact on QoL of chronic hand eczema	Impact on QoL of chronic hand eczema
8. Was/were the source(s) of effectiveness estimates used stated?	Yes / No / Not clear / NA	Yes	Yes
	Yes / No / Not clear / NA	RCT	Mainly RCTs
9. Were details of the design and results of the effectiveness study given (if based on a single study)?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement		
10. Were details of the methods of synthesis or meta-analysis of estimates given (if based on an overview of a number of effectiveness studies)?	Yes / No / Not clear / NA	NA	NA
	Comment - provide brief justification for judgement		

Question	Study		
		Van Gils, 2013 [12]	NICE TA177, 2008 [8]
11. Were the primary outcome measure(s) for the economic evaluation clearly stated?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement		
12. Were the methods used to value health states and other benefits stated?	Yes / No / Not clear / NA	NA	Yes
	Comment - provide brief justification for judgement		
13. Were the details of the subjects from whom valuations were obtained given?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement		From a RCT
14. Were productivity changes (if included) reported separately?	Yes / No / Not clear / NA	Yes	NA
	Comment - provide brief justification for judgement		
15. Was the relevance of productivity changes to the study question discussed?	Yes / No / Not clear / NA	Yes	NA
	Yes / No / Not clear / NA		
16. Were quantities of resources reported separately from their unit cost?	Yes / No / Not clear / NA	Partly	Yes
	Comment - provide brief justification for judgement	Only some unit costs reported	But not always presented, since they were confidential
17. Were the methods for the estimation of quantities and unit costs described?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement	RCT plus standard tariffs	Sources described
18. Were currency and price data recorded?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement	2010; €	2006/2007/2008; £
19. Were details of price adjustments for inflation or currency conversion given?	Yes / No / Not clear / NA	Yes	No
	Comment - provide brief justification for judgement	Inflated to 2010	
20. Were details of any model used given?	Yes / No / Not clear / NA	NA	Yes
	Comment - provide brief justification for judgement		Described in detail and presented graphically
21. Was there a justification for the choice of model used and the key parameters on which it was based?	Yes / No / Not clear / NA	NA	Yes
	Comment - provide brief justification for judgement		Discussed
	Yes / No / Not clear / NA	Yes	Yes

Question	Study		
	Van Gils, 2013 [12]	NICE TA177, 2008 [8]	
22. Was the time horizon of cost and benefits stated?	Comment - provide brief justification for judgement	54 weeks	3 years
23. Was the discount rate stated?	Yes / No / Not clear / NA	NA	Yes
	Comment - provide brief justification for judgement		
24. Was the choice of rate justified?	Yes / No / Not clear / NA	NA	Yes
	Comment - provide brief justification for judgement		Reference case
25. Was an explanation given if cost or benefits were not discounted?	Yes / No / Not clear / NA	NA	NA
	Comment - provide brief justification for judgement	1 year time horizon	
26. Were the details of statistical test(s) and CIs given for stochastic data?	Yes / No / Not clear / NA	Yes	No
	Comment - provide brief justification for judgement	Bootstrapping	PSA not conducted
27. Was the approach to sensitivity analysis described?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement		Deterministic
28. Was the choice of variables for sensitivity analysis justified?	Yes / No / Not clear / NA	Yes	Yes
	Yes / No / Not clear / NA		
29. Were the ranges over which the parameters were varied stated?	Yes / No / Not clear / NA	NA	Yes
	Comment - provide brief justification for judgement		
30. Were relevant alternatives compared? (That is, were appropriate comparisons made when conducting the incremental analysis?)	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement		
31. Was an incremental analysis reported?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement		
32. Were major outcomes presented in a disaggregated as well as aggregated form?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement		
33. Was the answer to the study question given?	Yes / No / Not clear / NA	Yes	Yes
	Comment - provide brief justification for judgement	Integrated care not cost-effective over 1 year	Alitreinoin is cost-effective compared to all alternatives
	Yes / No / Not clear / NA	Yes	Yes

Question	Study		
		Van Gils, 2013 [12]	NICE TA177, 2008 [8]
34. Did conclusions follow from the data reported?	Comment - provide brief justification for judgement		
	Yes / No / Not clear / NA	Yes	Yes
35. Were conclusions accompanied by the appropriate caveats?	Comment - provide brief justification for judgement	Missing data and power of economic evaluation	
	Yes / No / Not clear / NA	No	No
36. Were generalisability issues addressed?	Comment - provide brief justification for judgement		Relevant to the UK setting

Table S3. Risk of bias assessment of RCTs (Cochrane [3])

Author, year	Adequate sequence generation Was the allocation sequence adequately generated?	Allocation concealment Was allocation adequately concealed?	Blinding Was knowledge of the allocated interventions adequately prevented during the study?	Incomplete outcome data addressed Were incomplete outcome data adequately addressed?	Free of selective reporting Are reports of the study free of suggestion of selective outcome reporting?	Free of other bias Was the study apparently free of other problems that could put it at a high risk of bias?
Van Gils 2013 [12]	Yes, randomization performed	Yes, Pre-stratification was conducted	No, Patients, healthcare professionals and researchers were not blinded to treatment allocation, because of the nature of the intervention	No, Intent-to-treat approach	Yes	Yes

Table S4. Risk of bias assessment of cohort studies (CRD cohort checklist [4])

The following studies were not quality assessed:

- Thyssen (2010) [13] was not quality assessed because it was an epidemiological study incorporating a non-systematic review of the literature
- Apfelbacher (2012) [25], is a conference abstract and provided insufficient information to determine quality assessment.
- Diepgen (2012) [29], is a conference abstract and provided insufficient information to determine quality assessment.

Study (Endnote number)	Is there sufficient description of the groups and the distribution of prognostic factors?	Are the groups assembled at a similar point in their disease progression ?	Was the intervention / Treatment reliably ascertained ?	Were the groups comparable on all important confounding variables?	Was there adequate adjustment for the effect of these confounding variables?	Was a dose response relationship between intervention and outcome demonstrated ?	Was outcome assessment blind to exposure status?	Was follow-up long enough for the outcomes to occur?	What proportion of the cohort was followed up?	Were drop-out rates and reasons for dropout similar across intervention and unexposed groups?
Augustin 2011 [10]	NA	NA	NA	NA	NA	NA	NA	NA	100%	NA
Blank 2010 [9]	NA	NA	Yes	NA	NA	Yes	NA	Yes	NA	NA
Cvetkovski , 2005 [34]	YES (Age groups by gender, socioeconomic status; diagnostic subgroups; presence of AD; occupation at	NO (Participants had no or minimal, mild-moderate, or severe disease)	NA (Not an intervention study)	UNCLEAR (No details provided)	YES (Characteristics adjusted for age, sex, socioeconomic status, occupation, diagnosis and disease duration)	NA (Not an intervention study)	NA (Not an intervention study)	UNCLEAR (NR)	82%	NA (Not an intervention / Comparison study)

Study (Endnote number)	Is there sufficient description of the groups and the distribution of prognostic factors?	Are the groups assembled at a similar point in their disease progression ?	Was the intervention / Treatment reliably ascertained ?	Were the groups comparable on all important confounding variables?	Was there adequate adjustment for the effect of these confounding variables?	Was a dose response relationship between intervention and outcome demonstrated ?	Was outcome assessment blind to exposure status?	Was follow-up long enough for the outcomes to occur?	What proportion of the cohort was followed up?	Were drop-out rates and reasons for dropout similar across intervention and unexposed groups?
	<i>baseline; described for groups)</i>									
Cvetkovski , 2006 [35]	YES (Age groups by gender, socioeconomic status; diagnostic subgroups; presence of AD; occupation at baseline; depression; job change described for groups)	NO (Participants had no or minimal, mild-moderate, or severe disease)	NA (Not an intervention study)	UNCLEAR (No details provided)	YES (Comparison of a poor prognosis across different variables, such as age, sex, diagnoses, socioeconomic status, disease duration, and occupation)	NA (Not an intervention study)	NA (Not an intervention study)	YES (1-year follow-up)	71.24%	NA (Not an intervention / Comparison study)
Hald, 2009 [36]	YES (Baseline characteristics reported)	NO (Participants had moderate to	NA (Not an intervention/	UNCLEAR (No details provided)	YES (Risk of having a poor prognosis (yes	NA (Not an intervention study)	NA (Not an intervention study)	YES (6-month follow-up)	<75%	NA (Not an intervention /

Study (Endnote number)	Is there sufficient description of the groups and the distribution of prognostic factors?	Are the groups assembled at a similar point in their disease progression ?	Was the intervention / Treatment reliably ascertained ?	Were the groups comparable on all important confoundin g variables?	Was there adequate adjustment for the effect of these confounding variables?	Was a dose response relationship between intervention and outcome demonstrated ?	Was outcome assessment blind to exposure status?	Was follow-up long enough for the outcomes to occur?	What proportio n of the cohort was followed up?	Were drop- out rates and reasons for dropout similar across interventio n and unexposed groups?
		<i>very severe disease)</i>	<i>Comparison study)</i>		<i>/no) was analysed in a multivariable logistic regression model including the explanatory factors of patient delay, healthcare delay and total delay adjusted for the baseline characteristics sex and age, and furthermore, socioeconomic group and geography)</i>					<i>Comparison study)</i>

Study (Endnote number)	Is there sufficient description of the groups and the distribution of prognostic factors?	Are the groups assembled at a similar point in their disease progression ?	Was the intervention / Treatment reliably ascertained ?	Were the groups comparable on all important confounding variables?	Was there adequate adjustment for the effect of these confounding variables?	Was a dose response relationship between intervention and outcome demonstrated ?	Was outcome assessment blind to exposure status?	Was follow-up long enough for the outcomes to occur?	What proportion of the cohort was followed up?	Were drop-out rates and reasons for dropout similar across intervention and unexposed groups?
Josefson, 2006 [17]	NO (Limited baseline characteristics reported)	UNCLEAR (NR)	NA (Not an intervention/ Comparison study)	UNCLEAR (No details provided)	NO (No adjustments made)	NA (Not an intervention study)	NA (Not an intervention study)	YES (20-year follow-up)	81%	NA (Not an intervention / Comparison study)
Lerbaek, 2008 [21]	NO (Detailed patient characteristics not provided)	UNCLEAR (NR)	NA (Not an intervention/ Comparison study)	UNCLEAR (No details provided)	YES (Multiple regression analysis evaluated sex, zygosity, age at onset, socio-economic status, AD and positive patch test in 1997-98 on risk of sick leave and medical consultations.	NA (Not an intervention study)	NA (Not an intervention study)	YES (1-year follow-up)	41.5%	NA (Not an intervention / Comparison study)

Study (Endnote number)	Is there sufficient description of the groups and the distribution of prognostic factors?	Are the groups assembled at a similar point in their disease progression ?	Was the intervention / Treatment reliably ascertained ?	Were the groups comparable on all important confounding variables?	Was there adequate adjustment for the effect of these confounding variables?	Was a dose response relationship between intervention and outcome demonstrated ?	Was outcome assessment blind to exposure status?	Was follow-up long enough for the outcomes to occur?	What proportion of the cohort was followed up?	Were drop-out rates and reasons for dropout similar across intervention and unexposed groups?
					<i>Multiple regression analysis evaluated sex, zygosity, age at onset, socio-economic status, AD, positive patch test in 1997-98, current wet work, and duration of HE on risk of persistent hand eczema)</i>					
Malkonen, 2010 [15]	YES (Baseline characteristics reported)	NO (Some patients reported healing of OHE 7-14)	NA (Not an intervention/ Comparison study)	UNCLEAR (No details provided)	YES (Characteristics reported by sex)	NA (Not an intervention study)	NA (Not an intervention study)	YES (7-14 year follow-up)	80.1%	NA (Not an intervention / Comparison study)

Study (Endnote number)	Is there sufficient description of the groups and the distribution of prognostic factors?	Are the groups assembled at a similar point in their disease progression ?	Was the intervention / Treatment reliably ascertained ?	Were the groups comparable on all important confounding variables?	Was there adequate adjustment for the effect of these confounding variables?	Was a dose response relationship between intervention and outcome demonstrated ?	Was outcome assessment blind to exposure status?	Was follow-up long enough for the outcomes to occur?	What proportion of the cohort was followed up?	Were drop-out rates and reasons for dropout similar across intervention and unexposed groups?
		<i>years after diagnosis)</i>								
Meding, 2005 [19]	NO (Detailed patient characteristics not provided)	UNCLEAR (NR)	NA (Not an intervention/ Comparison study)	UNCLEAR (No details provided)	YES (Characteristics reported by sex)	NA (Not an intervention study)	NA (Not an intervention study)	YES (15-year follow-up)	<80%	NA (Not an intervention / Comparison study)
Mollerup, 2014 [37]	NO (Detailed patient characteristics not provided)	NO (Participants differed in terms of clinical disease severity)	NA (Not an intervention/ Comparison study)	UNCLEAR (No details provided)	YES (Characteristics reported by sex)	NA (Not an intervention study)	NA (Not an intervention study)	NO (No follow-up)	No follow-up	NA (Not an intervention / Comparison study)
Steengaard , 2016 [23]	NO (Baseline characteristics not reported)	UNCLEAR (NR)	UNCLEAR (No details provided)	UNCLEAR (No details provided)	UNCLEAR (No details provided)	UNCLEAR (No details provided)	UNCLEAR (No details provided)	YES (6-year follow-up)	44.71% dropout from 18-month follow-up	UNCLEAR (Details for intervention and control group dropouts not reported)

Table S5. Risk of bias assessment of cross-sectional studies - Adapted Newcastle Ottawa Scale (Herzog 2013 [5])

Study	Selection (max of 5 stars across all of scoring)			Comparability (max of 2 stars)	Outcome (max of 3 stars across all of scoring)		
	<p>1) Representativeness of the sample: a) Truly representative of the average in the target population. *(all participants or random sampling) b) Somewhat representative of the average in the target population. * (non-random sampling) c) Selected group of users (e.g. nurses) d) No description of the sampling strategy</p>	<p>2) Sample size a) Justified and satisfactory.* b) Not justified.</p>	<p>3) Non-respondents a) Comparability between respondents and non-respondents' characteristics is established, and the response rate is satisfactory. * b) The response rate is unsatisfactory, or the comparability between respondents and non-respondents is unsatisfactory. c) No description of the response rate or the characteristics of the responders and the non-responders.</p>	<p>4) Ascertainment of the exposure (risk factor) a) Validated measurement tool. ** b) Non-validated measurement tool, but the tool is available or described.* c) No description of the measurement tool.</p>	<p>1) The participants in different outcome groups are comparable, based on the study design or analysis. Confounding factors are controlled. a) The study controls for the most important factor (select one). * b) The study controls for any additional factor. *</p>	<p>1) Assessment of the outcome: a) Independent blind assessment. ** b) Record linkage. ** c) Self report. * d) No description.</p>	<p>2) Statistical test a) The statistical test used to analyse the data is clearly described and appropriate, and the measurement of the association is presented, including CIs and the probability level (p value). * b) The statistical test is not appropriate, not described or incomplete.</p>

<p>Agner, 2009 [24]</p>	<p>* (Somewhat representative of the average in the target population)</p>	<p>* (Justified)</p>	<p>- (No characteristics of the responders and the non-responders. No dropouts)</p>	<p>** (Validated measurement tool (HECSI score))</p>	<p>- (NR)</p>	<p>* (Self-report)</p>	<p>* (For comparison between groups, the Chi-square test was used, and when more than two groups were included the Kruskal–Wallis test was used. Multivariate linear regression was used to identify risk factors for high degree of severity)</p>
<p>Apfelbacher, 2016 [26, 27]</p>	<p>* (Somewhat representative of the average in the target population)</p>	<p>* (Justified)</p>	<p>- (No characteristics of patients included and not included in the registry; no dropouts)</p>	<p>** (Validated (PGA) measurement tool, unclear whether VAS score validated for CHE)</p>	<p>- (NR)</p>	<p>* (Severity assessed both objectively and subjectively)</p>	<p>* (Nominal and ordinal data were analysed by computing absolute (n) and relative frequencies (%). Continuous variables were analysed by computing means and SD. Chi-squared statistics/Fisher's exact test were used to identify variables that were significantly)</p>

							<p><i>associated with AH use in univariate analysis. Those variables that were significantly associated with the use of AH were entered into multivariate binary logistic regression models in a second step. Adjusted odds ratios (OR adj.) with corresponding 95% confidence intervals (CI) were computed</i></p>
--	--	--	--	--	--	--	---

<p>Cazzaniga, 2018 [28]</p>	<p>* (Somewhat representative of the average in the target population)</p>	<p>* (Justified)</p>	<p>* (Population characteristics reported; no dropouts)</p>	<p>** (Validated (PGA) measurement tool)</p>	<p>* (After variable categorisation, multiple logistic regression models were fitted by taking each time, sequentially, a variable as the predictor and the other as covariates. Adjustment by country was performed by combining, for every variable, regression coefficients in each stratum by means of fixed- or random-effect models)</p>	<p>* (Questionnaires)</p>	<p>* (Data presented as mean + SD or numbers with percentages for continuous and categorical variables, respectively. Continuous variables were categorized, for analysis purposes, using clinically meaningful thresholds as cut-offs. After variable categorisation, multiple logistic regression models were fitted by taking each time, sequentially, a variable as the predictor and the other as covariates. Adjustment by country was performed by combining, for every variable, regression coefficients in each</p>
-----------------------------	--	--------------------------	---	--	--	-------------------------------	--

							<i>stratum by means of fixed- or random-effect models)</i>
--	--	--	--	--	--	--	--

Dibenedetti, 2015 [18]	* (Somewhat representative of the average in the target population)	* (Justified)	- (Some patient details provided but no characteristics for non-responders; low response rate to patient survey (46% responded, 40.75% completed survey); very low response rate to physician survey (12.3%))	- (Self-rated and physician survey data)	- (NR)	* (Self-report)	- (Descriptive statistics, such as means, SDs, medians, and ranges, were reported for continuous variables and frequencies and percentages for categorical variables. no imputations were made for missing data; missing data were excluded from the analysis)
Diepgen, 2009 [30]	* (Somewhat representative of the average in the target population)	* (Justified)	- (No characteristics of the responders and the non-responders; no dropouts)	** (Validated measurement tool (HECSI score))	- (NR)	* (Self-report)	* (For the comparison of continuous measurements (i.e. age, HECSI score) between groups nonparametric tests were used (Mann–Whitney U-test and Kruskal–Wallis test))
Hald, 2008 [20]	* (Random sample from Civil Registration System)	* (Justified)	- (No characteristics of the responders)	** (Self-administered photographic guide previously)	* (Adjusted for gender and AD)	* (Self-report)	* (χ^2 tests and logistic regression models)

			and the non-responders; response rates 71% and 75%)	validated by evaluating the agreement between the severity assessment performed by and experienced dermatologist and patients)			
Herschel, 2013 [16]	* (Somewhat representative of the average in the target population)	* (Justified)	- (No characteristics of the responders and the non-responders. Response rate 56.3%)	** (Validated measurement tool (HECSI score) for severity)	- (NR)	* (Self-report)	* (The distribution of continuous variables between subgroups was compared using a t-test or Wilcoxon rank-sum test; frequencies were compared using the chi-squared test or the Fisher exact test)
Petersen, 2014 [22]	* (Somewhat representative of the average in the target population)	* (Justified)	* (No differences reported between responders and non-responders; response rate 70%)	** (Validated measurement tool (HECSI score) for severity)	* (Multivariate analysis including sex, age group and socioeconomic group)	* (Self-report)	* (Chi-squared tests were used when examining the associations between outcomes and explanatory categorical variables. The Wilcoxon signed-rank test was used to

						<p><i>compare paired data. AD, eczema on body locations other than the hands since 2007, baseline severity of hand eczema and periods with symptoms of hand eczema in the past 12 months at baseline were included in the multivariate analyses as these factors were found to be significant for a poor clinical prognosis or frequent eruptions at follow-up in the univariate analyses.</i></p> <p><i>ORs were presented with 95% CIs)</i></p>
--	--	--	--	--	--	---

Supplementary Material References

1. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ economic evaluation working party. *BMJ*. 1996;313(7052):275-83.
2. Higgins JPT, Savovic J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. *Cochrane Handbook for Systematic Reviews of Interventions* [Version 6][updated July 2019]. Cochrane. 2019. Available from: <https://training.cochrane.org/handbook/current/chapter-08>.
3. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011.
4. Centre for Reviews and Dissemination. *Systematic reviews: CRD's guidance for undertaking reviews in health care*. York: 2009. Available from: https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf.
5. Herzog R, Alvarez-Pasquin MJ, Diaz C, Del Barrio JL, Estrada JM, Gil A. Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. *BMC Public Health*. 2013;13:154.
6. Cortesi PA, Scalone L, Belisari A, Bonamonte D, Cannavo SP, Cristaudo A, *et al*. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. *Contact Derm*. 2014;70(3):158-68.
7. Fowler JF, Ghosh A, Sung J, Emani S, Chang J, Den E, *et al*. Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. *J Am Acad Dermatol*. 2006;54(3):448-57.
8. National Institute for Health and Care Excellence. *Single technology appraisal (STA) specification for manufacturer/sponsor submission of evidence*. London: National Institute for Health and Care Excellence; 2008. Available from: <https://www.nice.org.uk/guidance/ta177>.
9. Blank PR, Blank AA, Szucs TD. Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema - a long-term analysis from a Swiss perspective. *BMC Dermatol*. 2010;10(4):1-9.
10. Augustin M, Kuessner D, Purwins S, Hieke K, Posthumus J, Diepgen TL. Cost-of-illness of patients with chronic hand eczema in routine care: results from a multicentre study in Germany. *Br J Dermatol*. 2011;165(4):845-51.

11. Diepgen TL, Purwins S, Posthumus J, Kuessner D, John SM, Augustin M. Cost-of-illness analysis of patients with chronic hand eczema in routine care in Germany: focus on the impact of occupational disease. *Acta Derm Venereol.* 2013;93(5):538-43.
12. van Gils RF, Bosmans JE, Boot CRL, Rustemeyer T, van Mechelen W, van der Valk PGM, *et al.* Economic evaluation of an integrated care programme for patients with hand dermatitis. *Contact Derm.* 2013;69(3):144-52.
13. Thyssen JP, Johansen JD, Linneberg A, Menne T. The epidemiology of hand eczema in the general population-prevalence and main findings. *Contact Derm.* 2010;62(2):75-87.
14. Apfelbacher CJ, Ofenloch RF, Weisshaar E, Molin S, Bauer A, Mahler V, *et al.* Chronic hand eczema in Germany: 5-year follow-up data from the CARPE registry. *Contact Derm.* 2019;80(1):45-53.
15. Malkonen T, Alanko K, Jolanki R, Luukkonen R, Aalto-Korte K, Lauerma A, *et al.* Long-term follow-up study of occupational hand eczema. *Br J Dermatol.* 2010;163(5):999-1006.
16. Herschel S, Schmitt J, Bauer A. Satisfaction with medical treatment in patients with hand dermatitis - a cross-sectional study. *J Dtsch Dermatol Ges.* 2013;11(10):1007-13.
17. Josefson A, Farm G, Stymne B, Meding B. Nickel allergy and hand eczema--a 20-year follow up. *Contact Derm.* 2006;55(5):286-90.
18. Dibenedetti D, Baranowski E, Zelt S, Reynolds M, Sherrill B. Assessing United States patient and dermatologist experiences with severe chronic hand eczema. *J Clin Aesthet Dermatol.* 2015;8(11):19-27.
19. Meding B, Wrangsjö K, Jarvholm B. Fifteen-year follow-up of hand eczema: persistence and consequences. *Br J Dermatol.* 2005;152(5):975-80.
20. Hald M, Berg ND, Elberling J, Johansen JD. Medical consultations in relation to severity of hand eczema in the general population. *Br J Dermatol.* 2008;158(4):773-77.
21. Lerbaek A, Kyvik KO, Ravn H, Menne T, Agner T. Clinical characteristics and consequences of hand eczema - an 8-year follow-up study of a population-based twin cohort. *Contact Derm.* 2008;58(4):210-6.
22. Petersen AH, Johansen JD, Hald M. Hand eczema-prognosis and consequences: a 7-year follow-up study. *Br J Dermatol.* 2014;171(6):1428-33.
23. Steengaard SS, Bregnhøj A, Johansen JD. Hand eczema among hairdressing apprentices in Denmark following a nationwide prospective intervention programme: 6-year follow-up. *Contact Derm.* 2016;75(1):32-40.

24. Agner T, Andersen KE, Brandao FM, Bruynzeel DP, Bruze M, Frosch P, *et al.* Contact sensitisation in hand eczema patients-relation to subdiagnosis, severity and quality of life: a multi-centre study. *Contact Derm.* 2009;61(5):291-6.
25. Apfelbacher C, Weis M, Molin S, Weisshaar E, Bauer A, Mahler V, *et al.* Medical care of patients with chronic hand eczema: carpe registry. *Contact Derm.* 2012;66(Suppl 2):17.
26. Apfelbacher C, Weis M, Molin S, Bauer A, Mahler V, Schmitt J, *et al.* Which factors are associated with the use of systemic antihistamines in patients with chronic hand eczema? results from the CARPE registry. *J Eur Acad Dermatol Venereol.* 2016;30(1):50-6.
27. Apfelbacher C, Weiss M, Molin S, Bauer A, Mahler V, Schmitt J, *et al.* Antihistamine use in patients with chronic hand eczema: An analysis based on data from the German carpe registry. *Exp Dermatol.* 2015;24(3):E16.
28. Cazzaniga S, Apfelbacher C, Diepgen T, Ofenloch RF, Weisshaar E, Molin S, *et al.* Patterns of chronic hand eczema: a semantic map analysis of the CARPE registry data. *Br J Dermatol.* 2018;178(1):229-37.
29. Diepgen TL, Kuessner D. Sickness absences due to chronic hand eczema (CHE) in patients treated with oral alitretinoin under daily practice conditions: results of the toccata observational study comprising 522 workers. *Value Health.* 2012;15(4):A253.
30. Diepgen TL, Andersen KE, Brandao FM, Bruze M, Bruynzeel DP, Frosch P, *et al.* Hand eczema classification: a cross-sectional, multicentre study of the aetiology and morphology of hand eczema. *Br J Dermatol.* 2009;160(2):353-8.
31. Agner T. Job change in employees with occupational hand eczema. *Contact Derm.* 2018;79(Suppl 1):51.
32. Caroe TK, Ebbehøj NE, Bonde JPE, Vejlstrup SG, Agner T. Job change facilitates healing in a cohort of patients with occupational hand eczema. *Br J Dermatol.* 2017;179(1):80-87.
33. Caroe TK, Ebbehøj NE, Bonde JPE, Vejlstrup SG, Agner T. Occupational hand eczema and job change. *Br J Dermatol.* 2018;179(1):e68.
34. Cvetkovski RS, Rothman KJ, Olsen J, Mathiesen B, Iversen L, Johansen JD, *et al.* Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. *Br J Dermatol.* 2005;152(1):93-98.
35. Cvetkovski RS, Zachariae R, Jensen H, Olsen J, Johansen JD, Agner T. Prognosis of occupational hand eczema: a follow-up study. *Arch Dermatol.* 2006;142(3):305-11.

36. Hald M, Agner T, Blands J, Johansen JD, Danish Contact Dermatitis G. Delay in medical attention to hand eczema: a follow-up study. *Br J Dermatol.* 2009;161(6):1294-300.
37. Mollerup A, Veien NK, Johansen JD. An analysis of gender differences in patients with hand eczema- everyday exposures, severity, and consequences. *Contact Derm.* 2014;71(1):21-30.
38. van der Meer EWC, Boot CRL, van der Gulden JWJ, Jungbauer FHW, Coenraads PJ, Anema JR. Hand eczema among healthcare professionals in the Netherlands: prevalence, absenteeism, and presenteeism. *Contact Derm.* 2013;69(3):164-71.